Melchior Lauten

Dr. Melchior Lauten


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ESEnja Schneider
Enja Schneider
RWRiekje Winzer
Riekje Winzer
ARAnne Rissiek
Anne Rissiek
IRIsabell Ricklefs
Isabell Ricklefs
CMCatherine Meyer-Schwesinger
Catherine Meyer-Schwesinger
ETEva Tolosa
Eva Tolosa
Immune cells at sites of inflammation are continuously activated by local antigens and cytokines, and regulatory mechanisms must be enacted to control inflammation. The stepwise hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 generates adenosine, a potent immune suppressor. Here we report that human effector CD8 T cells contribute to adenosine production by releasing CD73-containing extracellular vesicles upon activation. These extracellular vesicles have AMPase activity, and the resulting adenosine mediates immune suppression independently of regulatory T cells. In addition, we show that extracellular vesicles isolated from the synovial fluid of patients with juvenile idiopathic arthritis contribute to T cell suppression in a CD73-dependent manner. Our results suggest that the generation of adenosine upon T cell activation is an intrinsic mechanism of human effector T cells that complements regulatory T cell-mediated suppression in the inflamed tissue. Finally, our data underscore the role of immune cell-derived extracellular vesicles in the control of immune responses.

17 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
RSRicha Sharma
Richa Sharma
SSSushree S. Sahoo
Sushree S. Sahoo
MHMasayoshi Honda
Masayoshi Honda
SGSophie L. Granger
Sophie L. Granger
CGCharnise Goodings
Charnise Goodings
MWMarcin W. Wlodarski
Marcin W. Wlodarski
Human telomere biology disorders (TBD)/short telomere syndromes (STS) are heterogeneous disorders caused by inherited loss-of-function mutations in telomere-associated genes. Here, we identify 3 germline heterozygous missense variants in the RPA1 gene in 4 unrelated probands presenting with short telomeres and varying clinical features of TBD/STS, including bone marrow failure, myelodysplastic syndrome, T- and B-cell lymphopenia, pulmonary fibrosis, or skin manifestations. All variants cluster to DNA-binding domain A of RPA1 protein. RPA1 is a single-strand DNA-binding protein required for DNA replication and repair and involved in telomere maintenance. We showed that RPA1E240K and RPA1V227A proteins exhibit increased binding to single-strand and telomeric DNA, implying a gain in DNA-binding function, whereas RPA1T270A has binding properties similar to wild-type protein. To study the mutational effect in a cellular system, CRISPR/Cas9 was used to knock-in the RPA1E240K mutation into healthy inducible pluripotent stem cells. This resulted in severe telomere shortening and impaired hematopoietic differentiation. Furthermore, in patients with RPA1E240K, we discovered somatic genetic rescue in hematopoietic cells due to an acquired truncating cis RPA1 mutation or a uniparental isodisomy 17p with loss of mutant allele, coinciding with stabilized blood counts. Using single-cell sequencing, the 2 somatic genetic rescue events were proven to be independently acquired in hematopoietic stem cells. In summary, we describe the first human disease caused by germline RPA1 variants in individuals with TBD/STS.

7 May 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
MLMelchior Lauten
Melchior Lauten
AAAndishe Attarbaschi
Andishe Attarbaschi
GCGunnar Cario
Gunnar Cario
MDMichaela Döring
Michaela Döring
OMOlga Moser
Olga Moser
Andreas Hermann GrollAndreas Hermann Groll
Andreas Hermann Groll
Background: Invasive mold disease (IMD) is a severe infectious complication in immunocompromised patients. The outcome of central nervous system (CNS) IMD is poor, but contemporary data, in particular in the pediatric setting, are lacking.Procedure: For this retrospective multicenter analysis, pediatric patients < 18 years with proven or probable CNS IMD receiving chemotherapy or undergoing allogeneic HSCT were reported by the local investigator. CNS IMD had to be diagnosed between 2007 and 2016. Proven CNS IMD was defined as compatible CNS imaging or macroscopic autopsy findings in conjunction with a positive microscopic or microbiological result in the brain tissue or cerebrospinal fluid. Probable CNS IMD was defined as compatible CNS imaging findings in combination with proven or probable IMD at a site outside the CNS.Results and conclusions: A total of 29 patients (median age, 14 years; 14 allogeneic HSCT recipients) were diagnosed with proven (n = 12) or probable (n = 17) CNS IMD. Aspergillus spp. was the most common fungal pathogen. All but one patient had IMD sites outside the CNS and eight patients (27.6%) were neurologically asymptomatic at diagnosis of CNS IMD. Forty‐nine percent of the patients survived CNS IMD; however, 46.7% of the survivors suffered from severe long‐term neurological sequelae. Our data suggest that (1) outcome of CNS IMD has improved in children as compared with previous series, (2) half of surviving patients suffer from severe neurological sequelae, and (3) imaging of the CNS should be performed in all children with IMD irrespective of neurological symptoms.

16 February 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
SSStefan Schönberger
Stefan Schönberger
MMMahsa Mir Mohseni
Mahsa Mir Mohseni
Jörg EllingerJörg Ellinger
Jörg Ellinger
GTGiao Vu Quynh Tran
Giao Vu Quynh Tran
MBMartina Becker
Martina Becker
DDDagmar Dilloo
Dagmar Dilloo
Purpose: Intracranial germ cell tumors (iGCT) comprise germinoma and non-germinoma. Their diagnosis predominantly relies on biopsy as only one-fifth of patients present with elevated biomarkers (AFP/ß-HCG) in serum or cerebrospinal fluid (CSF). MicroRNAs (miR/miRNA) have emerged as non-invasive biomarkers in extracranial GCT and may potentially facilitate non-invasive diagnosis in iGCT. Methods: We analyzed eight miRNAs in serum and CSF from the miR-371~373- and miR-302/367-clusters and four miRNAs differentially expressed in iGCT tissue (miR-142-5p/miR-146a-5p/miR-335-5p/miR-654-3p) from eight iGCT patients (age 10–33 years) and 12 control subjects by pre-amplified RT-qPCR. MiR-30b-5p (serum) and miR-204-5p (CSF) acted as reference genes. ΔCt-values were expressed as $$2^{{ - \Delta \Delta C_{{\text{t}}} }}$$ 2 - Δ Δ C t after standardization against controls. Results: Between iGCT and control patients’ serum ΔCt-values of miR-371a-3p (p = 0.0159), miR-372-3p (p= 0.0095, miR-367 (p = 0.0190), miR-302a (p = 0.0381) and miR-302d-3p (p = 0.0159) differed significantly. Discriminatory pattern in CSF was similar to serum as miR-371a (p = 0.0286), miR-372-3p (p = 0.0028), miR-367-3p (p = 0.0167) and miR-302d-3p (p = 0.0061) distinguished between patients and controls. Abundant $$2^{{ - \Delta \Delta C_{{\text{t}}} }}$$ 2 - Δ Δ C t levels of each of these miRNAs were found across all serum and CSF samples including biomarker-negative patients. Conclusion: With the largest data set so far, we underline the suitability of miR-371a, miR-372, miR-367 and miR-302d in serum and CSF for diagnosis of iGCT, particularly in biomarker-negative germinoma. Diagnosis of iGCT by miRNA analysis is a feasible and valid approach, particularly as serum can be readily obtained by a less invasive procedure. MiRNA analysis may discriminate iGCT from other tumors with similar radiological findings and may allow to monitor response to therapy as well as early relapse during follow-up.

15 November 2007 in Leukemia
Verified
Journal Article
Closed access
CKChristian Kratz
Christian Kratz
CNCharlotte Marie Niemeyer
Charlotte Marie Niemeyer
EJE Jüttner
E Jüttner
MKM Kartal
M Kartal
AWA Weninger
A Weninger
KWKatharina Wimmer
Katharina Wimmer

1 November 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
ATAnna Maria Testi
Anna Maria Testi
AAAndishe Attarbaschi
Andishe Attarbaschi
MVMaria Grazia Valsecchi
Maria Grazia Valsecchi
AMAnja Möricke
Anja Möricke
GCGunnar Cario
Gunnar Cario
MSMartin Schrappe
Martin Schrappe